Published research on Hydroxychloroquine sulfate
5 peer-reviewed publications on Hydroxychloroquine sulfate in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In 64 patients with resectable pancreatic adenocarcinoma, adding hydroxychloroquine to preoperative gemcitabine and nab-paclitaxel improved histopathologic response and showed evidence of autophagy inhibition and immune infiltration, while overall survival and relapse-free survival did not differ between arms.
- Clinical trial
In 112 patients with metastatic pancreatic cancer, adding hydroxychloroquine to gemcitabine and nab-paclitaxel did not improve overall survival at 12 months (41% vs 49%), although the overall response rate was higher in the hydroxychloroquine group (38.2% vs 21.1%).
- Clinical trial
In 40 patients with advanced solid tumors, the combination of hydroxychloroquine and dose-intense temozolomide was well tolerated, no maximum tolerated dose was reached, autophagic vacuole accumulation was observed in patient cells, and partial responses or stable disease occurred in a subset of melanoma patients.
- Clinical trial
In 25 patients with relapsed or refractory myeloma, combining hydroxychloroquine with bortezomib produced no protocol-defined dose-limiting toxicities, and of 22 evaluable patients 3 had very good partial responses, 3 had minor responses and 10 had stable disease.
- Review
The authors summarized five phase I trials combining hydroxychloroquine with vorinostat, temsirolimus, temozolomide or bortezomib and stated that these studies provided insights into tolerability of the combinations and guidance for the design of future trials.
Hydroxychloroquine sulfate in the catalog (specifications, pack sizes, Certificate of Analysis)